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Abstract
Spinal muscular atrophy (SMA) is a severe neuromuscular disorder caused by loss of the survival motor neuron 1 (SMN1)
gene. SMA is characterized by the degeneration of spinal cord motoneurons (MNs), progressive skeletal muscle
atrophy, and weakness. The cellular and molecular mechanisms causing MN loss of function are only partially known.
Recent advances in SMA research postulate the role of calpain protease regulating survival motor neuron (SMN)
protein and the positive effect on SMA phenotype of treatment with calpain inhibitors. We analyzed the level of
calpain pathway members in mice and human cellular SMA models. Results indicate an increase of calpain activity in
SMN-reduced MNs. Spinal cord analysis of SMA mice treated with calpeptin, a calpain inhibitor, showed an increase of
SMN, calpain, and its endogenous inhibitor calpastatin in MNs. Finally, in vitro calpeptin treatment prevented
microtubule-associated protein 1A/1B-light chain 3 (LC3) increase in MNs neurites, indicating that calpain inhibition
may reduce autophagosome accumulation in neuron prolongations, but not in soma. Thus, our results show that
calpain activity is increased in SMA MNs and its inhibition may have a beneficial effect on SMA phenotype through the
increase of SMN in spinal cord MNs.
Introduction
Survival motor neuron (SMN) is a ubiquitously
expressed protein located in the cytoplasm and the
nucleus of the cells, where it accumulates in Cajal bodies
and Gems (Gemini of Cajal bodies)1. SMN complex par-
ticipates in the assembly of small nuclear ribonuclear
proteins (snRNPs), which are involved in the splicing of
pre-mRNA2. SMN also accomplishes unique functions in
motoneurons (MNs), such as the transport of β-actin
mRNA to the growth cones of the axons3. SMN protein
deficiency is the basis of the neuromuscular disease spinal
muscular atrophy (SMA). SMA is a devastating disorder
that leads to progressive muscle weakness and atrophy
and represents the most common lethal genetic disease in
infants4–6. SMA is characterized by the degeneration of
spinal cord MNs caused by the mutation of the survival
motor neuron (SMN1) gene located at the telomeric
region of chromosome 5q3, which is responsible for the
production of SMN protein7. SMN2 gene, a nearly iden-
tical paralog of SMN1 in centromeric region of chromo-
some 5q3, is present in the human genome as part of an
inverted duplication. SMN2 expresses limited amounts of
functional full-length SMN protein. In SMA, SMN2 is
efficiently transcribed but cannot fully compensate for the
loss of SMN1 because a translationally silent, single-
nucleotide transition at position 6 in exon 7 causes pre-
dominant exon 7 skipping and results in an unstable
protein (SMNdelta7)8,9. The number of SMN2 gene
copies inversely correlates with the severity of SMA
phenotype and determines disease onset10. Although the
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genetic causes of SMA are well-known, the mechanisms
underlying lower MN degeneration remain unclear. For
example, MNs may have a uniquely high demand for
efficient messenger RNA splicing or disruption of a spe-
cific SMN function in MNs may cause SMA11. Knowledge
of the molecular and cellular mechanisms of MN
degeneration could be extremely relevant to prevention
and/or delay of SMA progression and to optimization of
recently developed therapies12,13.
The calpain protease system and autophagy are two
major regulatory pathways of the cell that have been cor-
related to neurodegenerative disorders14,15. Calpains are a
calcium-dependent family of proteases that participate in
calcium-mediated signaling pathways involved in cell pro-
cesses. Increases of cytosolic calcium in neurons activate
calpains and pathological conditions often result in their
overactivation16–18. Autophagy is a regulated process
responsible for the degradation of cytoplasmic proteins and
organelles by incorporating them into a double-membrane
vesicle (autophagosome) that is delivered to the lysosome19.
In SMA, autophagy is likely involved in MN death20.
Evidence exists that calpains exert modulatory effects at
multiple levels of autophagy14. In this context, we recently
reported that calpain inhibition increases the SMN protein
level in cultured spinal cord MNs and that administration
of calpeptin (a well-known calpain inhibitor) to SMA mice
models improves lifespan and motor function21. Based on
these results, the aim of the present work was to investi-
gate the calpain pathway in SMN-reduced MNs. We
examined calpain activation by monitoring α-fodrin frag-
ments and concluded that calpain activation is increased in
cultured human and mice SMA MNs, but not in SMA
fibroblasts. In vivo calpeptin treatment increases Smn,
calpain, and calpastatin protein levels in spinal cord MNs.
Finally, the addition of calpeptin to the culture medium
modulated the level of the LC3 autophagy marker in cul-
tured MNs. Our findings suggest that calpain can be
overactivated in SMN-reduced MNs and support
the hypothesis that calpeptin may be useful in SMA
therapies.
Materials and methods
SMA animals
Experiments involved two severe SMA mouse models.
FVB·Cg-Tg (SMN2)89AhmbSmn1tm1Msd/J (mutSMA) and
FVB·Cg-Grm 7Tg(SMN2)89Ahmb Smn 1tm1Msd Tg
(SMN2*delta7)4299Ahmb/J (SMNdelta7) mice were
kindly provided by Dr Josep E Esquerda and Dr Jordi
Caldero (IRBLleida-Universitat de Lleida). MutSMA
(Smn−/−; SMN2+/+) and SMNdelta7 (Smn−/−; SMN2+/+;
SMNΔ7+/+) were obtained by crossing heterozygous
animals. Littermates mutSMA/SMNdelta7 and WT
(Smn+/+; SMN2+/+ and Smn+/+; SMN2+/+; SMNΔ7 +/+,
respectively) were used for the experiments.
For MN purification, the heads of 12.5-day embryos
(E12.5) were snipped for genotyping; for in vivo treat-
ment, neonatal offspring were tattooed and a fragment of
the tail was obtained. The REDExtract-N-Amp Tissue
PCR Kit (Sigma) was used for genomic DNA extraction
and PCR setup, with the following primers: WT forward
5′-CTCCGGGATATTGGGATTG-3′, SMA reverse 5′-
GGTAACGCCAGGGTTTTCC-3′ and WT reverse 5′-
TTTCTTCTGGCTGTGCCTTT-3′. All procedures were
done in accordance with the Spanish Council on Animal
Care guidelines and approved by the Universitat de Lleida
Advisory Committee on Animal Services (Comité Ético de
Experimentación Animal CEEA 02-01/17).
Spinal cord MN isolation and culture
MN primary cultures were obtained from the spinal
cords of CD1 or WT and mutant SMA mouse embryos at
E12.5 essentially as described22,23. Isolated cells
(approximately 25,000 cells per spinal cord) were pooled
in culture medium and plated either in 4-well tissue
culture dishes (Nunc, Thermo Fisher Scientific) for wes-
tern blot analysis (50,000 cells/well) or using 15-mm glass
coverslips placed into the 4-well dishes for immuno-
fluorescence experiments (15,000 cells/well). Culture
medium was Neurobasal medium (Gibco, Thermo Fisher
Scientific) supplemented with B27 (2% v/v; Gibco), horse
serum (2% v/v; Gibco), L-glutamine (0.5 mM; Gibco) and
2-mercaptoethanol (25 μM; Sigma) and a cocktail of
brain-derived neurotrophic factor (BDNF), glial cell line-
derived neurotrophic factor (GDNF), ciliary neurotrophic
factor (CNTF), cardiotrophin-1 (CT-1), and hepatocyte
growth factor (HGF), as follows: 1 ng/ml BDNF, 10 ng/ml
GDNF, 10 ng/ml CNTF, 10 ng/ml CT-1, and 10 ng/ml
HGF (Peprotech). At 24 h after plating, 2 μg/ml of aphi-
dicolin (Sigma) was added to the culture medium and was
maintained throughout the experiment.
Calpeptin in vivo administration
Mice were individually housed in propylene cages
(33 cm × 18 cm × 14 cm) at an ambient temperature of
22 ± 2 °C and relative humidity of 40 ± 10%. Breeder mice
were provided with ad libitum water and rodent chow.
Mice were maintained on a 12 h:12 h light:dark cycle
(light period 07:30–19:30). SMNdelta7 and WT litter-
mates were assigned by simple randomization to receive
treatment or vehicle. Males and females were equally
included in the study. Calpeptin (Calbiochem) was dis-
solved in DMSO (50mM calpeptin) and injected at a dose
of 6 μg per gram of weight in saline solution. Vehicle
groups (Sham) received equal volumes of saline solution
with the same amount of DMSO. No blinded adminis-
tration was via subcutaneous (SC) injection in the inter-
scapular region once a day starting from P0 with a
polypropylene sterile syringe (Icogamma plus, 1 mL) and
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with a 30 G needle (BD Microlance). WT and mutant
animals received treatment or vehicle to a maximum of
postnatal day 8 (P8). Birth was defined as postnatal day 0
(P0) for the experiments.
Human fibroblast cell lines culture
Human fibroblast cell lines were obtained from the
Coriell Institute for Medical Research (Camden, NJ, USA).
The Coriell Cell Repository maintains the consent and
privacy of the donor samples. All the cell lines and culture
protocols in the present study were carried out in
accordance with the guidelines approved by institutional
review boards at the Universitat de Lleida and IRBLleida
research center. Two human fibroblast cell lines from
patients with SMA (3813: GM03813, SMAII; and 9677:
GM09677, SMAI) and one unaffected control (3814:
GM03814, Control) were purchased and cultured fol-
lowing manufacturer instructions. Cells were maintained
in minimum essential medium eagle (MEME) (Sigma)
supplemented with non-inactivated fetal bovine serum
(Gibco) (15% v/v), 0.5M of L-glutamine (Gibco), 1% (v/v)
of nonessential amino acids (Gibco), and 20 µg/ml
Penicillin–Streptomycin (Gibco). Cells were subcultured
every 3–4 days. For western blot analysis, cells were plated
at a density of 3000–4000 cells/cm2 in 35 mm tissue cul-
ture dishes and maintained in supplemented MEME
medium. After 2 days, total cell lysates were collected and
submitted to western blot analysis.
Differentiation of human-induced pluripotent stem cells
(iPSCs) to MNs
The human iPSCs used in the present work were pur-
chased from Coriell Institute for Medical Research. The
control cell line was GM23411*B iPSC (healthy non-fetal
tissue) and the SMA cell line was GM23240*B iPSC from
a patient with SMA type II (SMN2 2 copies; delta exon7–8
in SMN1). Control and SMA cells were differentiated to
MNs following the protocol described previously24 with
minor modifications. Briefly, the human iPSCs were cul-
tured on a layer of irradiated mouse embryonic fibroblasts
(MEFs) (Gibco). To generate neuroepithelial cells (NEP),
iPSCs were dissociated with Accutase (Gibco) following
manufacturer indications and plated on Geltrex (Gibco)-
coated plates in MEF-conditioned medium. After 24 h,
fresh neuroepithelial induction medium (NEPIM: DM/
F12:NBM 1:1 supplemented with B27, L-glutamine,
NEAA, all from Gibco; 0.1 mM ascorbic acid, Sigma; 3 μM
CHIR99021; 2 μM SB431512; 2 μM DMH1, all from
Cayman) was added. Cells were maintained in culture for
6 days, changing the medium every other day, and dis-
sociated with Accutase to generate MN progenitors
(MNP). MNPs were expanded with NEPIM containing
0.1 μM retinoic acid (Sigma), 0.5 μM purmorphamine
(Cayman), and 0.5 mM valproic acid (Sigma).
To induce MN differentiation, MNPs were detached
with Accutase and cultured in suspension in MN induc-
tion medium (NEPIM plus 0.5 μM retinoic acid, 0.1 μM
purmorphamine). Medium was changed every other day.
After 6 days, neurospheres were dissociated with Accu-
max (Invitrogen) and plated on laminin-coated plates in
MN maturation medium (MN induction medium sup-
plemented with 0.1 μM Compound E, Abcam; 20 ng/ml
CNTF and 20 ng/ml insulin-like growth factor 1, IGF-1,
Peprotech). For western blot analysis, cells were plated on
laminin-coated four-well dishes at 60,000 cells/cm2 of
density and maintained with MN maturation medium
during 6 days. For immunofluorescence experiments,
15,000 cells were plated on laminin-coated 1 cm2 glass
coverslips, maintained in the MN maturation medium,
and fixed in 4% paraformaldehyde in phosphate-buffered
saline (PBS).
Immunofluorescence
Lumbar region 1 and lumbar region 2 (L1 and L2)
segment of the spinal cords of calpeptin- or sham-treated
SMNdelta7 and WT mice was dissected and fixed in 4%
paraformaldehyde (Sigma) for 24 h. Three animals for
each condition were used. Cryopreservation with 30%
sucrose buffer was done 48 h before mounting segments
in tissue freezing medium (TBS, Electron Microscopy
Sciences), sectioned at 16 μm-thickness in a cryostat
(Leica CM3000). Slices were permeabilized with 0.3%
Triton X-100 and incubated for 1 h with 5% bovine serum
albumin (BSA) in PBS. Cultured human and mice MNs
were plated on glass coverslips and at the end of the
treatment were fixed with 4% paraformaldehyde (Sigma)
for 10 min followed by an additional min with cold
methanol (Sigma), then incubated for 2 h with 5% BSA
in PBS.
Primary antibody (anti-Islet1/2 antibody, 1:50, Cat. No.
39.4D5, Developmental Studies Hybridoma Bank; anti-
βIIITubulin antibody, 1:400, Cat. No. 5568; anti-LC3
antibody, 1:100, Cat. No. 2775, both from Cell Signaling;
anti-SMN antibody, 1:100, Cat. No. 610646, BD Bios-
ciences; anti-HB9 antibody, 1:75, Cat. No. ab92606; anti-
Calpastatin antibody, 1:100, Cat. No. ab28252; anti-ChAT
antibody, 1:100, Cat. No. ab18736, all from Abcam; anti-
Mu-Calpain antibody, 1:100, Cat. No. 9A4H8D3, Invi-
trogen) was diluted in 0.01% Triton X-100 and incubated
overnight. After washing, the secondary antibody was
added: anti-mouse ALEXA555 antibody, 1:400, Cat. No.
A21422; anti-rabbit ALEXA488 antibody, 1:400, Cat. No.
A11008, all from Invitrogen; anti-sheep ALEXA649,
1:400, Cat. No. 713-496-147; anti-mouse ALEXA488
antibody, 1:400, Cat. No. 715-546-150, both from Jackson
ImmunoResearch. Counterstain was performed with
NeuroTrace 530/615 Red Fluorescent Nissl Stain (1:150,
Life Technologies). Hoechst (1:400, Sigma) to identify
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nuclear localization in MNs soma. Samples were mounted
using Mowiol (Calbiochem) medium. Confocal images
were obtained using an FV10i Olympus confocal micro-
scope. Quantification of fluorescence was blinded per-
formed using the NIH ImageJ software.
Western blot analysis
Western blots were performed as previously descri-
bed22. Spinal cord tissue samples (WT sham n= 5; WT
calpeptin n= 4; mutSMA sham n= 6; and mutSMA cal-
peptin n= 4) were disaggregated using Direct Quant
100ST Buffer (DireCt Quant) and a G50 Tissue Grinder
(Coyote Bioscience). Total cell lysates of cultured cells or
tissue homogenates were resolved in sodium dodecyl
sulfate polyacrylamide gels and transferred onto poly-
vinylidene difluoride Immobilon-P transfer membrane
filters (Millipore) using an Amersham Biosciences semi-
dry Trans-Blot. The membranes were blotted with anti-
SMN antibody (1:5000, Cat. No. 610646, BD Biosciences),
anti-Calpain-1 antibody (1:1000, Cat. No. CG1928, Bio-
mol International Inc.), anti-Fodrin (Clone AA6) antibody
(1:4000, Cat. No. FG6090, Biomol International Inc.), and
anti-Calpastatin antibody (1:1000, Cat. No. AB28252,
Abcam). To control the specific protein content per lane,
membranes were reprobed with monoclonal anti-α-
tubulin antibody (1:50,000, Cat. No. T5168, Sigma). Blots
were developed using Luminata™ ForteWestern HRP
Substrate (Millipore).
Statistical analysis
All experiments were performed at least three inde-
pendent times. For animal studies we selected the mini-
mum number of mice to have enough subjects to
accomplish experimental aims. No samples or animals
were excluded from the analysis. Values were expressed as
mean ± SEM. Statistical analyses were performed using
GraphPad Prism (version 5) (GraphPad Software Inc.).
Differences between groups were assessed with two-tailed
Students t test or by one-way ANOVA with Bonferroni
multiple comparisons post-test. Similar variances between
the compared groups were assumed. Values were con-
sidered significant when p < 0.05.
Results
Calpain activity is increased in SMA cultured spinal cord
MNs
In two SMA mouse models, in vivo treatment with the
calpain inhibitor calpeptin has been shown to improve
survival and motor phenotype21. In order to determine
whether calpain pathway is altered in Smn-reduced MNs,
mutSMA and SMNdelta7 E12.5 embryos were genotyped
and the spinal cords of WT and mutant mice were dis-
sected. MNs were isolated and cultured in the presence of
a cocktail of neurotrophic factors. After 4 days, in vitro
protein extracts were collected and submitted to western
blot analysis using anti-SMN antibody, anti-α-fodrin
antibody, anti-Calpain-1 antibody, or anti-calpastatin
antibody. As expected, Smn protein level was sig-
nificantly reduced in total cell lysates of cultured MNs
from both SMA models (mutSMA, 0.39 ± 0.04, p < 0.0001;
SMNdelta7, 0.16 ± 0.03, p < 0.0001), compared to the WT
controls (Fig. 1). Degradation of α-fodrin to the 150/
145 kDa-specific fodrin breakdown products is a well
characterized method to evaluate calpain activation by
western blot analysis25. Therefore, an anti-α-fodrin anti-
body was used to measure α-fodrin fragments in order to
define calpain activation in WT and SMA samples. The
levels of 150/145 kDa product in protein extracts obtained
from mutSMA (2.30 ± 0.43, p= 0.014) (Fig. 1a) and
SMNdelta7 (2.37 ± 0.8, p= 0.029) (Fig. 1b) cultured MNs
were significantly increased compared to the respective
WT controls. However, calpain protein level did not differ
significantly between SMA cultured MNs and WT con-
trols (Fig. 1a, b).
Taken together, these results suggested an increase of
calpain activity in cultured Smn-reduced MNs without an
increase of calpain protein level. To elucidate whether
increased calpain activity was caused by a reduction of
calpastatin protein level, we evaluated the level of this
endogenous calpain inhibitor by western blot analysis. We
observed that calpastatin was not significantly modified in
mutSMA and SMNdelta7 conditions (Fig. 1), suggesting
that increased calpain activity in these cells is not caused
by reduced levels of calpastatin.
Calpain activity is increased in human SMA iPSCs
differentiated MNs, but not in SMA fibroblasts
To further evaluate changes of calpain pathway mem-
bers in SMN-reduced cells, we next explored protein
levels of calpain, calpastatin, and fodrin in two human
SMA cellular models: fibroblasts and MNs differentiated
from iPSC (Figs. 2 and 3).
Total protein cell lysates of 2-day cultured fibroblasts
were submitted to western blot analysis using the fol-
lowing antibodies: anti-SMN antibody, anti-calpain
antibody, anti-α-fodrin antibody, or anti-calpastatin
antibody. Results showed that SMN protein level was
significantly reduced in cell lysates from SMA fibro-
blasts (SMAII, 0.47 ± 0.07; and, SMAI, 0.41 ± 0.06, p <
0.0001) compared to the clinically unaffected control.
In SMN-reduced fibroblasts we observed that 150/
145 kDa α-fodrin degradation product was significantly
decreased (SMAII, 0.63 ± 0.04; and, SMAI, 0.64 ± 0.09,
p < 0.0003) compared to control condition, indicating
that calpain activity was reduced in these cells. Protein
level of calpain and calpastatin were not significantly
modified in SMA fibroblasts compared to the control
(Fig. 2).
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Human SMA and control iPSC cells were in vitro dif-
ferentiated to MNs. Immunofluorescence analysis showed
that MN markers such as Islet 1/2, HB9, and ChAT
besides the neuronal indicator βIIITubulin were expres-
sed by these cells after 6 days in the presence of MN
maturation medium, suggesting that human SMA and
Control iPSC cells were properly differentiated to MNs
(Fig. 3a) following the protocol described24. As expected,
SMN level was reduced in SMA samples compared to
Control. Six days after differentiation, cells were fixed and
SMN immunostaining with anti-SMN antibody was per-
formed. Using the NIH ImageJ software, quantification of
average of fluorescence units showed that SMN was
reduced in SMA (54.7 ± 1.8, number of cells= 76; p <
0.0001) MNs compared to Control (113.3 ± 5.7, number
of cells= 90) (Fig. 3b). Western blot analysis of total
protein lysates using an anti-SMN antibody demonstrated
that SMN protein was significantly decreased in SMA
(0.32 ± 0.06, p < 0.0001) samples compared to Control
(Fig. 3c). When calpain, 150/145 kDa α-fodrin and cal-
pastatin were analyzed in protein extracts of 6 days dif-
ferentiated MNs, we observed the following results: (i)
150/145 kDa α-fodrin degradation product was sig-
nificantly increased in SMA samples (1.29 ± 0.10,
Fig. 1 Fodrin 150/145 breakdown products are increased in cultured embryonic spinal cord MNs from SMA mice. Embryonic mouse
motoneurons (MNs) were isolated from wild-type (WT: a–c) or mutSMA (a, c) or SMNdelta7 (b, c) genotyped embryos and cultured in the presence
of a neurotrophic factors cocktail. Four days after plating, protein extracts were obtained and submitted to western blot analysis using anti-SMN
antibody (a, b), anti-calpain 1 antibody (a, b), anti-fodrin antibody (a, b), or anti-calpastatin antibody (c). Membranes were reprobed with an anti-α-
tubulin antibody. Graph values represent the expression of Smn, calpain, 150/145 fodrin product or calpastatin vs. α-tubulin and correspond to the
quantification of 4 or 6 independent experiments. Asterisks indicate differences using Student t test (*p < 0.05; ***p < 0.0001).
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p= 0.0278) compared to the Control condition; (ii) cal-
pain protein level was significantly reduced in SMA
samples (0.68 ± 0.06, p= 0.0010) compared to the Control
condition; and (iii) calpastatin protein levels were not
significantly different between SMA and Control condi-
tions (p= 0.720) (Fig. 3c). These results indicate an
increase of calpain activity together with reduced levels of
calpain protein in SMA human differentiated MNs.
Calpeptin treatment increases Smn protein level and
reduces α-fodrin degradation product in SMA mutant mice
Calpeptin is a cell-permeable calpain inhibitor which
increases Smn protein level in cultured isolated mice spinal
cord MNs. In addition, in vivo calpeptin treatment extends
SMA mice survival and improves motor function21. To fur-
ther examine the cellular effect of in vivo calpeptin admin-
istration we started a treatment protocol using the FVB.Cg-
Grm7Tg(SMN2)89Ahmb Smn1tm1Msd Tg (SMN2*delta7)
4299Ahmb/J (SMNdelta7) mouse model. This severe SMA
mouse model has a life expectancy of 10 days, and calpeptin
treatment increases lifespan to 14 days21. SC injection of
calpeptin (6 μg per gram of weight in saline solution) was
administrated once a day starting from postnatal day 0 (P0)
to postnatal day 8 (P8). Vehicle (Sham) and calpeptin treated
mice were sacrificed at P8. In order to determine the level of
Smn protein and calpain activation in spinal cord of treated
animals, total protein extracts of lumbar fragments were
obtained and submitted to western blot using anti-SMN
antibody and anti-α-fodrin antibody. Results showed that
Smn level was significantly increased in protein extracts from
calpeptin-treated SMNdelta7 mice (0.58 ± 0.03, p= 0.0095;
n= 4 treated animals) compared to the vehicle-treated
control extracts (SMNdelta7 Sham) (Fig. 4a). Even it was
observed a slightly increase of Smn in calpeptin-treated WT
(1.34 ± 0.03; n= 4 treated animals), no significant differences
were observed compared to the Sham control condition
(0.85 ± 0.14, p= 0.32; n= 4 treated animals). We also ana-
lyzed the level of 150/145 kDa α-fodrin fragments in protein
extracts of calpeptin-treated mice. As shown in Fig. 4a, 150/
145 kDa α-fodrin fragment was significantly increased in
SMNdelta7 Sham (3.26 ± 0.84) compared to WT Sham
(1.29 ± 0.19, p= 0.021), indicating an increased calpain
activity in SMNdelta7 spinal cord protein extracts. On the
other hand, calpeptin-treated SMNdelta7 condition showed
150/145 kDa α-fodrin (1.11 ± 0.29) levels, which is not dif-
ferent to WT Sham controls, but it is significantly reduced
compared to SMNdelta7 Sham (p= 0.031). Together these
results suggest that SMNdelta7 spinal cord protein extracts
show increased calpain activity which is prevented by SC
injection of calpeptin.
In order to know whether Smn protein level is increased
in lumbar spinal cord MNs soma of SMNdelta7 calpeptin-
Fig. 2 Analysis of fodrin, calpain, and calpastatin protein levels in cultured human SMA fibroblasts. Control (unaffected) and SMAII and SMAI
patient fibroblast cell lines were plated in 35 mm culture dishes and maintained in the presence of supplemented MEME medium. Two days after
plating, cell lysates were obtained and submitted to western blot analysis using anti-SMN antibody, anti-calpain 1 antibody, anti-fodrin antibody, or
anti-calpastatin antibody. Membranes were reprobed with an anti-α-tubulin antibody. Graph values represent the expression of SMN, calpain, 150/
145 fodrin product, or calpastatin vs. α-tubulin and correspond to the quantification of six independent experiments. Asterisks indicate differences
using one-way ANOVA with Bonferroni multiple comparisons post-test (**p < 0.0003; ***p < 0.0001).
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Fig. 3 Calpain protein levels are reduced in human SMA iPSC differentiated MNs. a Representative immunofluorescence images of 3-day
differentiated motoneurons (MNs) in Control and spinal muscular atrophy (SMA), showing Islet 1/2 (red), βIIITubulin (green left section), Hoechst
(blue), and HB9 (green right section). b Representative immunofluorescence images of Control and SMA MNs using an anti-SMN antibody and
Hoechst staining after 3 days of culture. Graph represents the mean of relative SMN fluorescence (red) measured in cell soma, corresponding to the
quantification of three independent experiments ± SEM. Asterisks indicate significant differences using Student t test (p < 0.0001). c Protein extracts of
3-day differentiated human MNs were submitted to western blot analysis and probed with anti-SMN antibody, anti-calpain 1 antibody, anti-fodrin
antibody, or anti-calpastatin antibody. Membranes were reprobed with an anti-α-tubulin antibody, used as a loading control. Graphs represent the
expression of SMN, calpain, 150/145 fodrin products or calpastatin, corresponding to the quantification of at least three independent experiments ±
SEM. Asterisks indicate differences using Student t test (*p < 0.05; **p < 0.001; ***p < 0.0001). Scale bar, 20 μm.
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Fig. 4 (See legend on next page.)
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treated mice, we performed an immunofluorescence
analysis using an anti-SMN antibody. Mice were sub-
cutaneously treated daily with calpeptin from P0 and
sacrificed at P8. Lumbar fragments of spinal cords of
Sham- or calpeptin-treated WT and SMNdelta7 mice
were dissected and cryostat sections of 16 μm-thickness
were obtained. MNs were identified in spinal cord sec-
tions using Nissl stain, and Smn corrected total cell
fluorescence was measured in Nissl-positive MNs. As
predictable, quantification of the relative average of
fluorescence units demonstrated that Smn level was sig-
nificantly reduced in Sham-treated SMNdelta7 cells
(49.1 ± 3.8, p < 0.0001) compared to the WT Sham control
(222.8 ± 30.8). No significant differences of Smn fluores-
cence were observed in WT Sham- and WT calpeptin-
treated cells (232.2 ± 38, p= 0.848) (Fig. 4b). However,
calpeptin treatment increased significantly Smn relative
fluorescence in SMNdelta7 MNs soma (108.2 ± 9.4, p <
0.0001) compared to sham-treated SMNdelta7, indicating
that calpain inhibition increases Smn level in spinal
cord MNs.
To further analyze the calpain pathway in spinal cord
MNs of calpeptin-treated mice, we decided to measure by
immunofluorescence the level of calpain and calpastatin
in cell soma. To this end, lumbar spinal cord sections of
8 days sham- and calpeptin-treated WT or SMNdelta7
mice were processed for immunofluorescence using an
anti-calpain antibody or an anti-calpastatin antibody.
Results indicate that SMNdelta7 Sham-treated (47.87 ±
4.91) MNs showed significantly reduced levels of calpain
compared to WT Sham-treated (469.4 ± 52.78, p < 0.0001)
control condition. Calpeptin treatment significantly
increases calpain level in both WT (702.7 ± 74.16) and
SMNdelta7 (531.8 ± 71.62) conditions compared to WT
(p < 0.05) and SMNdelta7 (p < 0.0001) Sham-treated
control samples, respectively. This result indicated that
calpeptin treatment regulates calpain protein level in
spinal cord MNs soma. On the other hand, the analysis of
calpastatin levels in the same experimental context
showed a comparable profile to the one observed in
calpain immunofluorescence measures. Sham-treated
SMNdelta7 (30.2 ± 4.9) MNs exhibited decreased calpas-
tatin levels compared to sham WT (141.6 ± 35.9, p < 0.05)
controls (Fig. 5b). Calpeptin treatment increased calpas-
tatin average fluorescence units in both WT (253.7 ± 32.9)
and SMNdelta7 (137.0 ± 32.1) MNs soma compared to
WT (p < 0.05) and SMNdelta7 (p < 0.05) sham-treated
conditions, respectively. These results together suggest
that in vivo calpain inhibition using calpeptin adminis-
tration increases endogenous levels of calpain and
calpastatin.
Effect of calpeptin treatment on LC3 level in cultured SMA
spinal cord MNs
Autophagy is deregulated in SMA models20,26. Our
previous studies demonstrated that the autophagosome
marker LC3-II is increased in mice Smn-reduced spinal
cord MNs in vivo and in vitro27,28. To corroborate
autophagy alterations in the SMNdelta7 mouse model, we
measured LC3-II protein level in cultured spinal cord
MNs. WT and SMNdelta7 E12.5 embryos were genotyped
and isolated MNs were cultured in the presence of the
neurotrophic factors cocktail. After 6 or 12 days in culture
WT and SMNdelta7 protein extracts were collected and
submitted to western blot analysis using an anti-LC3
antibody. LC3-II protein level was significantly increased
in total cell lysates of mutant MNs at 6 and 12 days
in vitro (day 6: 1.98 ± 0.65, p= 0.04; day 12: 1.58 ± 0.30,
p= 0.02) compared to the WT controls (Fig. 6a).
In many disease conditions and models calpains were
shown to negatively regulate autophagy14. In this context,
our next objective was to elucidate whether autophagy
modulation can affect calpain activity in cultured MNs.
To this end, 150/145 kDa α-fodrin degradation products
were measured in the presence of the mTOR-dependent
or the mTOR-independent autophagy inducers resvera-
trol29 and trehalose30, respectively. E12.5 CD1 mouse
spinal cords were dissected and MNs were isolated and
cultured during 6 days in the presence of neurotrophic
factors. Cells were left untreated (Control) or treated with
(see figure on previous page)
Fig. 4 Effect of in vivo calpeptin treatment on Smn and fodrin levels in the spinal cord of SMNdelta7 mice. Wild-type (WT) and SMNdelta7
genotyped mice were daily treated with vehicle or 6 μg/g of calpeptin and sacrificed at 8 post-natal days. a Total cell lysates of spinal cords were
submitted to western blot analysis using anti-SMN antibody or anti-fodrin antibody. Membranes were reprobed with an anti-α-tubulin antibody, used
as a loading control. Graphs represent the expression of Smn or 150/145 fodrin products and correspond to the quantification of at least four treated
animals from three independent experiments ± SEM. Asterisks indicate differences using Student t test (*p < 0.05; **p < 0.005). b Representative
immunofluorescence image of lumbar spinal cord section using Nissl staining. Red circle indicates ventral MNs pool localization. Scale bar, 200 µm.
c Representative immunofluorescence images of ventral horn spinal cord sections of WT and SMNdelta7 vehicle- or calpeptin-treated mice using an
anti-SMN antibody (green) and Nissl staining (red). Scale bar, 10 μm. Nissl and Hoechst (blue) staining were used to identify MNs soma and nucleus,
respectively. Graph represents the mean of relative Smn fluorescence measured in MNs soma, corresponding to the quantification of at least 50
neurons per condition from sections of minimum 4 treated animals ± SEM. Asterisks indicate significant differences using one-way ANOVA with
Bonferroni multiple comparisons post-test (***p < 0.0001). Images were acquired with an FV10I confocal microscope (Olympus) using the ×60
objective and the same microscopy settings. Images were not submitted to any post-capture manipulation.
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25 µM calpeptin or 50 nM resveratrol for 12 h; or with
25 µM calpeptin or 100 mM trehalose for 6 h. After
treatment, cell lysates were obtained and submitted to
western blot using an anti-α-fodrin antibody or an anti-
LC3 antibody. Results showed that calpeptin, resveratrol
and trehalose treatments significantly increased LC3-II
protein level (calpeptin 12 h: 1.27 ± 0.15, p= 0.03; cal-
peptin 6 h: 1.45 ± 0.19, p= 0.01; resveratrol 1.21 ± 0.05,
p < 0.0001; trehalose 1.30 ± 0.21, p= 0.01) compared to
untreated controls (Fig. 6b). As expected, calpeptin
treatment significantly reduced 150/145 kDa α-fodrin
fragments (12 h: 0.62 ± 0.09, p= 0.001; 6 h: 0.69 ± 0.04,
p < 0.0001) compared to the untreated controls. Never-
theless, resveratrol and trehalose addition did not sig-
nificantly modify α-fodrin fragments level (1.03 ± 0.12,
p= 0.76 and 1.04 ± 0.05, p= 0.54, respectively) compared
to untreated controls (Fig. 6b). These results suggest that
the autophagy inducers resveratrol and trehalose did not
modulate calpain activity in cultured spinal cord MNs.
We next analyzed whether calpeptin treatment regulate
LC3 level in Smn-reduced MNs. SMNdelta7 E12.5
embryos were genotyped and the spinal cords of WT and
mutant mice were dissected. MNs were isolated and
cultured in the presence of neurotrophic factors. After
6 days in vitro, cells were treated with 25 µM calpeptin for
3 h and protein extracts were collected and submitted to
western blot analysis using an anti-SMN antibody or an
anti-LC3 antibody. LC3-II protein level was significantly
increased in total cell lysates of mutant cultured MNs
(SMNdelta7, 1.28 ± 0.05, p= 0.0024) compared to the
WT controls (Fig. 6c). Addition of calpeptin to the culture
medium significantly increased LC3-II protein in WT
cultures (1.29 ± 0.05, p= 0.0034) compared to untreated
WT controls. However, even LC3-II level was increased in
calpeptin-treated SMNdelta7 condition (1.67 ± 0.28, p=
0.17), the differences were not statistically significant
compared to untreated SMNdelta7 controls (Fig. 6c).
Since MNs are highly polarized cells, we decided to
examine LC3 protein in cell soma and neurites by
immunofluorescence in calpeptin-treated and untreated
conditions. To this end, isolated MNs from WT and
SMNdelta7 were cultured in the presence of neurotrophic
factors. Six days after plating cells were treated with
25 μM calpeptin during 3 h. Cultures were fixed and
submitted to immunofluorescence using an anti-LC3
antibody. The number of fluorescent LC3 puncta was
quantified using the NIH ImageJ software28. As expected,
results shown in Fig. 6 exhibit a significant increase of
LC3 in neurites and soma of SMNdelta7 (SMNdelta7
Control, neurites: 0.64 ± 0.05 spots; soma: 97.71 ±
9.1 spots) conditions compared to the WT (WT Control,
neurites: 0.27 ± 0.03 spots, p < 0.0001; soma: 39.72 ± 3.24,
p < 0.0001) controls. Calpeptin treatment significantly
increases LC3 spots in WT MNs soma (64.1 ± 9.34, p <
0.05) compared to non-treated control cells, but a similar
effect was not observed in neurites. However, calpeptin
treatment clearly prevents LC3 increase in neurites of
SMNdelta7 MNs (SMNdelta7 Calpeptin 0.4 ± 0.003, p <
0.0001) compared to the SMNdelta7 control cultures,
indicating that calpeptin treatment reduced autophago-
somes in neurites of SMA mice. We did not observe the
same effect in MN soma. When fluorescent LC3 spots
were measured in calpeptin-treated SMNdelta7 cell soma
(93.67 ± 6.3), there were no significant differences com-
pared to control non-treated SMNdelta7 cells. This result
suggests that calpain inhibition increases LC3 spots in
MN soma and prevents autophagosome accumulation in
neurites.
Discussion
The molecular mechanisms leading to MN degenera-
tion in SMA disease are poorly understood. SMN protein
reduction causes cellular changes which directly or
indirectly provoke the deregulation of several processes
involved in cell homeostasis, including autophagy and
apoptosis31. Nonetheless, intracellular pathways related
to neurotrophic communication or calcium regulation
may be impaired in SMA pathology and contribute to
modifying the evolution of the disease32. In this context,
we have previously demonstrated that treating SMA mice
with the calpain inhibitor calpeptin had a positive effect
on survival and motor function21. The present work
found an increase of calpain activity in cultured SMA
spinal cord MNs and human differentiated SMA MNs.
Calpain is a calcium-regulated protease implicated in
neuronal injury, neurodegenerative disorders, and
(see figure on previous page)
Fig. 5 Calpeptin in vivo treatment increase calpain and calpastatin in SMA spinal cord MNs. Wild-type (WT) and SMNdelta7 genotyped mice
were daily treated with vehicle (Sham) or 6 μg/g of calpeptin (Calpeptin) and sacrificed at 8 post-natal days. Representative immunofluorescence
images of ventral horn spinal cord sections of WT and SMNdelta7 vehicle- or calpeptin-treated mice using anti-calpain 1 antibody (green) (a) or anti-
calpastatin antibody (green) (b) and Nissl staining (red). Scale bar, 10 μm. Nissl and Hoechst (blue) staining were used to identify MNs soma and
nucleus, respectively. Graph represents the mean of relative calpain (a) or calpastatin (b) fluorescence measured in MNs soma, corresponding to the
quantification of at least 50 neurons per condition from sections of minimum 3 treated animals ± SEM. Asterisks in a and b indicate significant
differences using one-way ANOVA with Bonferroni multiple comparisons post-test (*p < 0.05; **p < 0.001; ***p < 0.0001). Images were acquired with
an FV10I confocal microscope (Olympus) using the ×60 objective and the same microscopy settings. Images were not submitted to any post-capture
manipulation.
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neuronal aging processes. Its overactivation has been
detected in many neurodegenerative disorders, including
amyotrophic lateral sclerosis33. Cellular functions of
calpains are related to the regulation of the proteolysis of
many substrates, including enzymes and structural pro-
teins. This implies the control of several primary cell
functions such as motility or gene expression34. Degra-
dation of 270 kDa α-fodrin (also called αII-spectrin) to
the 150/145 kDa-specific fodrin breakdown product has
been attributed to the activation of calpain25. We
observed an increase of these calpain-specific fodrin
products in mice cultured spinal cord MNs and differ-
entiated human SMA MNs, but not in human SMA
cultured fibroblasts, suggesting an increase of calpain
activity in SMN-reduced MNs. This increase of calpain
activity was not the consequence of an increase of calpain
protein, because no increase from basal level occurred
in cultured mice MNs, and a decrease was observed in
human differentiated SMA MNs and in MNs soma of
SMNdelta7 mice.
Reports of the activation mechanisms of calpains have
been controversial. The calcium concentrations neces-
sary for activation of calpains are in the micro- to milli-
molar range, which is rather beyond the nanomolar
calcium levels in cells under normal physiological con-
ditions. Nevertheless, this apparent contradiction can be
resolved because the cellular microenvironment may
provide the sufficient calcium concentration35. Calpain
activity can be compartmentalized and calcium changes
localized in some neuronal sections in SMA may con-
tribute to the increase of calpain activity in these parti-
cular spaces36,37.
However, damaging calpain overactivation has been
detected in other neurodegenerative disorders, such as
Alzheimer disease, amyotrophic lateral sclerosis, Par-
kinson disease, or the group of polyQ disorders14. This
calpain overactivation can be caused by an increase of
intracellular calcium concentration or by a reduction
of the natural endogenous inhibitor calpastatin. Cal-
pains form a complex with calpastatin, the only known
endogenous protein inhibitor of calpain activity in
cells34. Depletion of endogenous calpastatin has been
described in mouse models of several neurodegenera-
tive disorders38–40. Likewise, calpastatin reduction and
increased calpain activity have been related to bio-
chemical changes related to the breakdown of cytos-
keletal proteins and activation of cdk5 and caspase-3,
leading to MN degeneration in hSOD1G93A mice16.
Western blot analysis of calpastatin levels in cultured
SMA MNs showed no changes in this protein in these
cells; however, when immunofluorescence experiments
were performed in spinal cords of P8 SMNdelta7 mice,
we observed calpastatin reduction in MNs soma. In
vivo calpeptin treatment prevents calpastatin reduc-
tion, which suggests that calpain activity can also reg-
ulate the members of the pathway. In this context, we
observed that basal levels of calpain were increased by
calpeptin treatment, reinforcing the hypothesis that
calpain activity regulates calpastatin and calpain pro-
tein levels in spinal cord MNs. Interestingly, in vivo
calpeptin treatment also increased SMN protein in
spinal cord extracts and in MNs soma. It is well-known
that SMN is a proteolytic target of calpain and its
activity modulates SMN level21,28,41,42. Therefore, our
results strongly suggest that the in vivo beneficial effect
observed in calpeptin-treated SMA mice21 can be
mediated to some extent by SMN protein increase
in MNs.
(see figure on previous page)
Fig. 6 In vitro analysis of LC3 autophagosome marker in calpeptin treated cells: soma and neuritis. a WT and SMNdelta7 spinal cord
motoneurons (MNs) were isolated and cultured in the presence of a neurotrophic factors cocktail. After 6 and 12 days in vitro protein extracts were
obtained and submitted to western blot analysis using an anti-LC3 antibody. Membranes were reprobed with an anti-α-tubulin antibody, used as a
loading control. Graph represents the expression of LC3-II corresponding to the quantification of three independent experiments ± SEM. Asterisks
indicate differences using Student t test (*p < 0.05). b Isolated CD1 E12.5 mouse MNs were cultured in the presence of a neurotrophic factors cocktail.
Six days after plating cells were left untreated or treated with 25 µM calpeptin or 50 nM resveratrol for 12 h; or with 25 µM calpeptin or 100 mM
trehalose for 6 h. Total cell lysates were submitted to western blot using an anti-α-fodrin antibody or an anti-LC3 antibody. Membranes were
reprobed with an anti-α-tubulin antibody, used as a loading control. Graphs represent the expression of LC3-II or 150/145 fodrin products
corresponding to the quantification of 3 independent experiments ± SEM. Asterisks indicate differences using Student t test (*p < 0.05; **p < 0.005;
***p < 0.0001). c WT and SMNdelta7 MNs were cultured in the presence of a neurotrophic factors cocktail. Six days after plating cells were left
untreated or treated with 25 µM calpeptin during 3 h. Cells lysates were obtained and submitted to western blot using an anti-SMN antibody or an
anti-LC3 antibody. Membranes were reprobed with an anti-α-tubulin antibody, used as a loading control. Graphs represent the expression of LC3-II
corresponding to the quantification of three independent experiments ± SEM. Asterisks indicate differences using Student t test (**p < 0.005). d WT
and SMNdelta7 MNs were isolated and cultured during 6 days in the presence of a neurotrophic factors cocktail. Cells were treated with 25 μM
calpeptin or left untreated during 3 h and immunofluorescence was performed using anti-LC3 antibody (green) (d, e). Representative confocal
images of neurites (d) and soma (e) of immunostained MNs. Hoechst (blue) dye was used to identify MN nucleus. Graphs represent the mean of LC3
positive puncta measured in neurites (d) or soma (e) of wild-type (WT) and SMNdelta7 control or calpeptin treated MNs, corresponding to the
quantification of tree independent experiments ± SEM. Asterisks indicate significant differences using one-way ANOVA with Bonferroni multiple
comparisons post-test (*p < 0.05; ***p < 0.0001). Scale bar, 20 μm.
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Calpains are considered as modulator proteases that can
regulate protein functions, and therefore various cellular
pathways, including autophagy. In many disease envir-
onments and models, calpains are known to negatively
regulate autophagy. Consequently, enhanced calpain
activation can contribute to the compromised activation
of this degradation pathway. Various studies have found
that the impact of calpains on autophagy occurs on
multiple levels, such as reduction of autophagy initiation
or switching from autophagy to apoptosis14. Several
neurodegenerative disorders exhibit an overactivation of
calpains and disturbances of the autophagic pathway. In
SMA disease, autophagy pathway is deregulated26–28 and
inhibition of autophagy delays MN degeneration and
extends lifespan of SMA mice20. From the results pre-
sented in these previous reports it can be suggested that
LC3-II autophagosome marker is augmented in SMN-
reduced MNs. In the present work we show that LC3-II
protein level is increased in the SMNdelta7 mutant iso-
lated MNs compared to the WT controls. It has been
previously described that calpeptin treatment increases
the number of autophagosomes-like structures in COS-7
cells43; accordingly, calpeptin treatment increased LC3-II
protein level in WT conditions, but no significant differ-
ences were observed in SMNdelta7 cultures. By immu-
nofluorescence, we showed that calpeptin treatment
increased LC3 spots in MN somas of WT cells. However,
we did not observe the same effect in neurites: LC3 spots
in WT neurites did not increase after calpeptin treatment.
Interestingly, calpeptin treatment prevented LC3 increase
in neurites in SMA cells, but not in cell soma. Accumu-
lation of autophagosomes in axons can perturb
microtubule-associated axonal transport, which can be
linked to neurodegeneration affecting autophagic flux.
Our results suggest that calpeptin treatment may regulate
autophagosome accumulation in neurites. This effect
would prevent the neurite collapse that can lead to MN
degeneration.
In conclusion, calpain pathway is an intracellular pro-
teolytic mechanism involved in the development of sev-
eral neurodegenerative disorders. The present study
found an increase of calpain activity in SMN-reduced
cells. We suggest that the positive modifier effect of
in vivo calpeptin treatment on SMA mice survival and
motor phenotype could be the result of SMN protein
and LC3 autophagosome protein regulation in SMA MNs
and could offer a viable therapeutic approach. Although
infants with SMA appear to have a genetic defect in
common, the clinical course of this disease shows high
variability. The analysis of new SMA modifiers belonging
to several intracellular regulatory pathways which con-
tribute differently to disease progression may lead to the
discovery of new treatment strategies for this devastating
condition.
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